- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01646112
Uncertain Genetic Test Results for Lynch Syndrome
Living in Lynch Syndrome Limbo: Exploring the Meaning of Uncertain Genetic Test Results
Background:
- Individuals have varying tolerances for receiving ambiguous information. However, not much is known about how ambiguous genetic testing information is received. Also, not much is known about how at-risk individuals internalize and process these results. More information is needed about how this information affects a person s life.
- Lynch Syndrome is a genetic condition that carries a high risk of colon cancer and other cancers. Individuals at risk for Lynch Syndrome can have genetic testing for it. The test may confirm a diagnosis and determine actions that can be taken. Results from genetic testing can also affect the perspectives of relatives who might also be affected. However, genetic testing can also produce variants of unknown significance (VUS). VUS are data that may not provide enough information to make decisions. Researchers want to study people who have received a VUS result for genetic testing for Lynch Syndrome.
Objectives:
- To learn more about the impact and experience of receiving a VUS for Lynch Syndrome genetic testing.
Eligibility:
- Individuals at least 18 years of age who have recently had a VUS result on a genetic test for Lynch Syndrome.
Design:
- Participants will be asked to answer demographic questions. They will also have a 45- to 60-minute phone interview.
- During the phone interview, participants will be asked a series of questions about their diagnosis. They will be asked about how they received the result and how they felt right after receiving it. They will also discuss who they have spoken to about the result.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION AND EXCLUSION CRITERIA:
Individuals who have received a VUS for Lynch Syndrome must be over 18, have telephone access and speak English. Individuals will be excluded if they ve received their results less than 3 months earlier or more than 6 years ago.
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Publications and helpful links
General Publications
- Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003 May;72(5):1117-30. doi: 10.1086/375033. Epub 2003 Apr 3. Erratum In: Am J Hum Genet. 2003 Sep;73(3):709.
- Kresse A, Jacobowitz DM, Skofitsch G. Distribution of calcitonin gene-related peptide in the central nervous system of the rat by immunocytochemistry and in situ hybridization histochemistry. Ann N Y Acad Sci. 1992 Jun 30;657:455-7. doi: 10.1111/j.1749-6632.1992.tb22798.x. No abstract available.
- Boks DE, Trujillo AP, Voogd AC, Morreau H, Kenter GG, Vasen HF. Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer. 2002 Nov 10;102(2):198-200. doi: 10.1002/ijc.10667.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Metabolic Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Genetic Diseases, Inborn
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Colorectal Neoplasms
- Neoplastic Syndromes, Hereditary
- DNA Repair-Deficiency Disorders
- Colorectal Neoplasms, Hereditary Nonpolyposis
Other Study ID Numbers
- 999912126
- 12-HG-N126
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HNPCC
-
Universitaire Ziekenhuizen KU LeuvenCompletedLynch Syndrome | Hereditary Non-polyposis Colon Carcinoma | HNPCCBelgium
-
Vejle HospitalCompletedColorectal Cancer | Lynch Syndrome | HNPCCDenmark
-
National Human Genome Research Institute (NHGRI)CompletedHNPCC | Hereditary Nonpolyposis Colon CancerUnited States
-
Vejle HospitalCompletedColorectal Cancer | Lynch Syndrome | HNPCCDenmark
-
University of PennsylvaniaEpigenomics, IncCompletedColorectal Cancer | Lynch Syndrome | Familial Adenomatous Polyposis | Map Syndrome | HnpccUnited States
-
White Plains HospitalRecruitingPancreatic Cancer | Pancreatic Adenocarcinoma | Lynch Syndrome | Pancreas Cancer | HNPCC | Familial Pancreatic Cancer | Hereditary Pancreatitis | BRCA 1/2 | FAMMM | Familial Atypical Multiple Mole Melanoma | Peutz Jeghers SyndromeUnited States